FDA Office Of New Drug Restructuring To Include OTC Resource Reallocation
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of New Drugs restructuring will more efficiently allocate the agency's resources and staff, particularly with respect to OTCs, Director John Jenkins, MD, said
You may also be interested in...
OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
FDA Guidances On Actual Use Studies, Switches Will Clarify Agency Processes
A guidance on conducting actual use trials for Rx-to-OTC switch candidates is under development, according to FDA Office of New Drugs Director John Jenkins, MD
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.